semaglutide cardiovascular outcomes trial Wegovy shown to reduce risk of heart attack, stroke in major Semaglutide cardiovascular align more – Effects of semaglutide on mortality,

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

In mice with asthma, increasing glutathione with NAC lowered inflammation and improved the symptoms

Only one study looked at those with gastroparesis

Using electronic health records of 113 million patients in the U.S., of whom more than 1.6 million had T2D and were treated with GLP-1 receptor agonists, insulins or metformin, the Ohio team found that GLP-1 receptor agonists were associated with significantly lower risk of several OACs versus insulin, but not metformin

For most people, these prices make long-term treatment financially impossible